Early evidence of the predictive value of tumor mutation burden to the outcome to CPI treatment was generated by Snyder et al. by examining a series of outlier responses in melanoma patients who received anti-CTLA-4 therapy [68]. This evidence concerns the gene CTLA4 and melanoma.